BRASILIA (Reuters) – Brazilian lab and hospital group DASA S.A. said on Wednesday it has agreed to conduct clinical Phase 2 and 3 trials in Brazil for a COVID-19 vaccine developed by COVAXX, a unit of privately-owned United Biomedical Inc.
COVAXX co-founder Peter Diamedes said in a remote press conference that the UB-612 multitope peptide-based vaccine is currently undergoing Phase 1 tests in Taiwan. DASA medical director Gustavo Campana said a protocol for the tests will be submitted to Brazil’s health regulator ANVISA in December.
(Reporting by Anthony Boadle; Editing by Chizu Nomiyama)
